In that pooled analysis, the association between pCR and favorable outcomes was most pronounced in tumor types typically associated with poor prognosis, such as triple-negative breast cancer, in which a 76% reduction in the risk of an EFS event was reported, and HER2-positive breast cancer, in which a 41% reduction in the risk of an EFS event was reported. This evidence concerns the gene ERBB2 and breast carcinoma.